-
Mashup Score: 1Burnout in Hematology Reaches Critical Levels Amid Emotional Strain, Long Hours: Adela Perolla, MD, PhD - 22 hour(s) ago
Burnout is rising sharply in hematology due to emotional strain, long hours, and high patient demands, according to Adela Perolla, MD, PhD, impacting both physician well-being and patient care.
Source: www.ajmc.comCategories: General Medicine NewsTweet
-
Mashup Score: 0AI-Based Tool for Classifying Acute Leukemia Subtypes Shows Promise in Global Study: Merlin Engelke, MS - 23 hour(s) ago
An artificial intelligence (AI)-driven machine learning model was refined and validated internationally to accurately classify acute leukemia subtypes from routine laboratory data, according to Merlin Engelke, MS, offering a potential tool for improving diagnosis worldwide.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
Merlin Engelke, MS, explains at #EHA2025 that an #AI-driven machine learning model was refined & validated to accurately classify acute #leukemia subtypes from routine laboratory data, offering a potential tool for improving diagnosis worldwide. Tune in: https://t.co/tQxZhtWkxY https://t.co/AOImtdptsM
-
-
Mashup Score: 0
Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
#Revumenib shows promise for high-risk patients with acute myeloid leukemia (#AML) with specific genetic mutations, demonstrating efficacy with no new safety signals, according to data in posters presented at #EHA2025. Learn more here: https://t.co/o2j7J7vcgw https://t.co/fYCtPXUqqY
-
-
Mashup Score: 0ADVANCE Trial Supports DKRd as New Standard of Care for Newly Diagnosed Multiple Myeloma: Ola Landgren, MD, PhD - 2 day(s) ago
Ola Landgren, MD, PhD, shares ADVANCE trial results, which show that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (DKRd) improves outcomes in newly diagnosed multiple myeloma.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
In part 2 of our interview with Dr Ola Landgren ahead of #EHA2025, he shares ADVANCE trial results, which show that adding #daratumumab to carfilzomib-lenalidomide-dexamethasone mproves outcomes in newly diagnosed #multiplemyeloma. Watch here: https://t.co/sfqINu1RIa https://t.co/EHvUDD1Tiu
-
-
Mashup Score: 0
Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible or deferred newly diagnosed multiple myeloma.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
Two posters presented at the 2025 European Hematology Association Congress (#EHA2025) support combination therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible or deferred newly diagnosed #multiplemyeloma: https://t.co/H3oRd2w5kw
-
-
Mashup Score: 2Epcoritamab Improves Outcomes, HRQOL in Patients With Relapsed/Refractory Follicular Lymphoma - 3 day(s) ago
Both monotherapy and combination therapy containing epcoritamab had high response rates and survival benefits when compared with usual care.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
Patients w/ relapsed/refractory follicular #lymphoma reported consistent or increased response rates, survival benefits, & health-related quality of life when taking some form of #epcoritamab, according to 3 posters presented at #EHA2025. Learn more: https://t.co/bpeahEd0MQ https://t.co/PswUwE91G1
-
-
Mashup Score: 0ADVANCE Trial Aims to Modernize Frontline Multiple Myeloma Care: Ola Landgren, MD, PhD - 3 day(s) ago
Ola Landgren, MD, PhD, lead investigator of the ADVANCE clinical trial, outlines the study’s goal of advancing modern, minimal residual disease–guided treatment approaches.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
In this clip, Dr Ola Landgren, lead investigator of the #ADVANCE clinical trial, outlines the study’s goal of advancing modern, minimal residual disease–guided treatment approaches. He will present the findings this Sunday at #EHA2025. Watch here: https://t.co/HrEGG1bbfF https://t.co/IeDT27zI0k
-
-
Mashup Score: 0EHA: European Hematology Association - 3 day(s) ago
The European Hematology Association’s annual meeting presents the latest news in hematology and its subspecialties with evidence-based approaches to diagnosis and treatment, recent clinical and translational research data, and more.
Source: www.ajmc.comCategories: General Medicine NewsTweet-
We are on-site in Milan, Italy, for #EHA2025! Stay up to date with our coverage here: https://t.co/W39FrVUlPI https://t.co/4L0cWueZmZ
-
-
Mashup Score: 0
A novel blood test offers affordable early detection of Alzheimer disease, enhancing awareness and intervention opportunities during Alzheimer’s and Brain Awareness Month.
Source: www.ajmc.comCategories: General Medicine News, General Journals & SocietTweet-
A new blood test could make early Alzheimer’s detection more accessible and affordable. This advancement comes during Alzheimer’s & Brain Awareness Month—spotlighting the power of early diagnosis. Read the latest AJMC article: https://t.co/jd1idO7Ly8 https://t.co/BPX9igWpTT
-
-
Mashup Score: 3
Transforming the Management of Cardiovascular Disease at Scale Ty J. Gluckman, MD, FACC, FAHA Providence Tigard, OR Francoise Marvel, MD John Hopkins University Baltimore, MD Melissa Magwire, RN, MSN Cardiometabolic Center Alliance Shawnee, KS Nihar Desai, MD Yale School of Medicine New Haven,CT Ty J. Gluckman, MD, FACC, FAHA Associate Professor and Chief Providence Tigard, OR Francoise Marvel, MD John Hopkins University Baltimore, MD Melissa Magwire, RN, MSN Cardiometabolic Center Alliance Shawnee, KS
Source: www.ajmc.comCategories: General Medicine NewsTweet-
Experts discuss the role of implementation science in bridging research and practice, with a focus on cardiovascular disease. Learn more in this video from AJMC, sponsored by Amgen. Watch here: https://t.co/HVukX18ROu #sponsored
-
At #EHA2025, Dr Adela Perolla told #AJMC that #burnout is rising sharply in #hematology due to emotional strain, long hours, and high patient demands, impacting both physician well-being and patient care. Watch here: https://t.co/ztgPGoqqKe https://t.co/UL18T1ihDI